BIT Capital GmbH Makes New $717,000 Investment in Palisade Bio, Inc. $PALI

BIT Capital GmbH bought a new position in shares of Palisade Bio, Inc. (NASDAQ:PALI) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 305,000 shares of the company’s stock, valued at approximately $717,000. BIT Capital GmbH owned 0.20% of Palisade Bio as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds also recently modified their holdings of PALI. Geode Capital Management LLC raised its holdings in shares of Palisade Bio by 5,780.7% during the fourth quarter. Geode Capital Management LLC now owns 1,565,452 shares of the company’s stock worth $3,681,000 after purchasing an additional 1,538,832 shares during the period. Goldman Sachs Group Inc. acquired a new stake in shares of Palisade Bio during the fourth quarter worth $1,310,000. TD Asset Management Inc acquired a new position in Palisade Bio during the 4th quarter valued at about $480,000. Jefferies Financial Group Inc. acquired a new position in Palisade Bio during the 4th quarter valued at about $110,000. Finally, Total Clarity Wealth Management Inc. acquired a new position in Palisade Bio during the 4th quarter valued at about $70,000. 11.79% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

PALI has been the subject of a number of recent analyst reports. Wall Street Zen upgraded shares of Palisade Bio from a “sell” rating to a “hold” rating in a research report on Saturday, February 28th. Stifel Nicolaus initiated coverage on shares of Palisade Bio in a research report on Wednesday, February 25th. They issued a “buy” rating and a $5.00 target price for the company. HC Wainwright initiated coverage on shares of Palisade Bio in a research report on Thursday, March 26th. They issued a “buy” rating and a $7.00 target price for the company. Finally, Wolfe Research initiated coverage on shares of Palisade Bio in a research report on Thursday, April 9th. They issued an “outperform” rating and a $7.00 target price for the company. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Palisade Bio presently has a consensus rating of “Moderate Buy” and an average target price of $10.20.

Palisade Bio Price Performance

NASDAQ PALI opened at $1.74 on Friday. The company has a 50 day simple moving average of $2.00 and a 200-day simple moving average of $1.93. The firm has a market capitalization of $302.03 million, a price-to-earnings ratio of -1.72 and a beta of 1.52. Palisade Bio, Inc. has a 52-week low of $0.53 and a 52-week high of $2.86.

Palisade Bio (NASDAQ:PALI) last posted its quarterly earnings results on Tuesday, May 12th. The company reported ($0.05) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.01). On average, analysts predict that Palisade Bio, Inc. will post -0.21 EPS for the current year.

Palisade Bio Company Profile

Palisade Bio, Inc is a clinical‐stage biotechnology company focused on pioneering localized immunotherapies for the treatment of cancer and inflammatory diseases. The company leverages a proprietary prodrug platform designed to activate therapeutic agents selectively within the tumor microenvironment or sites of inflammation. Its core strategy centers on stimulating the innate immune system via toll‐like receptor 9 (TLR9) agonism to drive targeted immune responses while minimizing systemic exposure and toxicity.

The company’s lead product candidate, PDS0108, is an intratumoral TLR9 agonist prodrug currently in Phase 1/2 clinical trials for patients with advanced solid tumors.